Exelon

Product NDC: 0078-0325
11-digit product format: 000780325
Labeler code: 0078
Product ID: 0078-0325_cb8c7caf-a61a-48a7-933d-4720ee22cdbc
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: rivastigmine tartrate
Dosage form: CAPSULE
Route: ORAL
Labeler: Novartis Pharmaceuticals Corporation
Application: NDA020823
Marketing category: NDA
Marketing start: 2000-04-30
Marketing end: 0000-00-00
Substance: RIVASTIGMINE TARTRATE
Active strength: 5 mg/1
Pharmacologic classes: Cholinesterase Inhibitor [EPC],Cholinesterase Inhibitors [MoA]
NDC exclude flag: No
Listing certified through: 2020-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 5 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Source date
excluded product	product	0078-0325		D	Discontinued by firm	2026-08-10
excluded package	package	0078-0325	0078-0325-06	D	Discontinued by firm	2026-08-10
excluded package	package	0078-0325	0078-0325-08	D	Discontinued by firm	2026-08-10
excluded package	package	0078-0325	0078-0325-15	D	Discontinued by firm	2026-08-10
excluded package	package	0078-0325	0078-0325-44	D	Discontinued by firm	2026-08-10

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 60 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	0078-0325-15	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	0078-0325-06	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	0078-0325-08	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	0078-0325-44	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	0078-0325-15	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	0078-0325-06	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	0078-0325-08	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	0078-0325-44	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	0078-0325-15	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	0078-0325-06	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	0078-0325-08	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	0078-0325-44	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	0078-0325-15	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	0078-0325-06	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	0078-0325-08	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	0078-0325-44	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	0078-0325-15	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	0078-0325-06	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	0078-0325-08	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	0078-0325-44	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	0078-0325-15	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	0078-0325-06	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	0078-0325-08	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	0078-0325-44	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	0078-0325-15	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	0078-0325-06	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	0078-0325-08	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	0078-0325-44	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	0078-0325-15	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	0078-0325-06	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	0078-0325-08	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	0078-0325-44	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	0078-0325-15	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	0078-0325-06	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	0078-0325-08	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	0078-0325-44	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	0078-0325-15	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	0078-0325-06	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	0078-0325-08	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	0078-0325-44	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	0078-0325-15	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	0078-0325-06	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	0078-0325-08	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	0078-0325-44	`367a005e9d99…`	`383a685ebd0f…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded product	product		`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	0078-0325-15	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	0078-0325-06	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	0078-0325-08	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	0078-0325-44	`557ba5c1ecfa…`	`9c80585c8c6e…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 4 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	RLD / RS	Approval date
N020823-003	EXELON	RIVASTIGMINE TARTRATE	EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21
N020823-004	EXELON	RIVASTIGMINE TARTRATE	EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21
N020823-005	EXELON	RIVASTIGMINE TARTRATE	EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21
N020823-006	EXELON	RIVASTIGMINE TARTRATE	EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 5 · 164 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-02-19 14:30 UTC	2026-02	N020823-003	EXELON	EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N020823-004	EXELON	EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N020823-005	EXELON	EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N020823-006	EXELON	EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N020823-003	EXELON	EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N020823-004	EXELON	EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N020823-005	EXELON	EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N020823-006	EXELON	EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N020823-003	EXELON	EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N020823-004	EXELON	EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N020823-005	EXELON	EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N020823-006	EXELON	EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N020823-003	EXELON	EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N020823-004	EXELON	EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N020823-005	EXELON	EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N020823-006	EXELON	EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N020823-003	EXELON	EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N020823-004	EXELON	EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N020823-005	EXELON	EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N020823-006	EXELON	EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N020823-003	EXELON	EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N020823-004	EXELON	EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N020823-005	EXELON	EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N020823-006	EXELON	EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N020823-003	EXELON	EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N020823-004	EXELON	EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N020823-005	EXELON	EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N020823-006	EXELON	EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N020823-003	EXELON	EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N020823-004	EXELON	EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N020823-005	EXELON	EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N020823-006	EXELON	EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N020823-003	EXELON	EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N020823-004	EXELON	EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N020823-005	EXELON	EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N020823-006	EXELON	EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N020823-003	EXELON	EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N020823-004	EXELON	EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N020823-005	EXELON	EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N020823-006	EXELON	EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL	RLD	2000-04-21	`d06236e962d9…`

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	TE code	Order	Source SHA-256
2019-07-19 19:46 UTC	2019-07	N020823-003	AB	1	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N020823-004	AB	1	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N020823-005	AB	1	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N020823-006	AB	1	`ea99ee380514…`

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
f5a24cc0-a293-4838-b663-7e454a66c2c3	Product name	5	20200513
64bcf1db-afe4-78b0-8e9c-f7cb25e1b791	Product name	6	20171121

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
0078-0325-06	EA - Each	0078-0325	642dfab0-5a45-4ff9-8342-ea10d0050ab1	1	2012-07-24
0078-0325-44	EA - Each	0078-0325	cf4ae08d-e63d-4a66-9fd2-754fbd4ace64	1	2012-07-24
0078-0325-61	EA - Each	0078-0325	1ae1fd3f-5eca-43be-980e-d0912e380397	1	2012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
RIVASTIGMINE TARTRATE	ACTIVE INGREDIENT	9IY2357JPE	EXELON (RIVASTIGMINE TARTRATE) CAPSULE EXELON (RIVASTIGMINE TARTRATE) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]	14
RIVASTIGMINE	ACTIVE MOIETY	PKI06M3IW0	EXELON (RIVASTIGMINE TARTRATE) CAPSULE EXELON (RIVASTIGMINE TARTRATE) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]	14
CELLULOSE, MICROCRYSTALLINE	INACTIVE INGREDIENT	OP1R32D61U	EXELON (RIVASTIGMINE TARTRATE) CAPSULE EXELON (RIVASTIGMINE TARTRATE) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]	14
CITRIC ACID MONOHYDRATE	INACTIVE INGREDIENT	2968PHW8QP	EXELON (RIVASTIGMINE TARTRATE) CAPSULE EXELON (RIVASTIGMINE TARTRATE) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]	14
D&C YELLOW NO. 10	INACTIVE INGREDIENT	35SW5USQ3G	EXELON (RIVASTIGMINE TARTRATE) CAPSULE EXELON (RIVASTIGMINE TARTRATE) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]	14
FERRIC OXIDE RED	INACTIVE INGREDIENT	1K09F3G675	EXELON (RIVASTIGMINE TARTRATE) CAPSULE EXELON (RIVASTIGMINE TARTRATE) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]	14
FERRIC OXIDE YELLOW	INACTIVE INGREDIENT	EX438O2MRT	EXELON (RIVASTIGMINE TARTRATE) CAPSULE EXELON (RIVASTIGMINE TARTRATE) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]	14
GELATIN	INACTIVE INGREDIENT	2G86QN327L	EXELON (RIVASTIGMINE TARTRATE) CAPSULE EXELON (RIVASTIGMINE TARTRATE) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]	14
HYPROMELLOSES	INACTIVE INGREDIENT	3NXW29V3WO	EXELON (RIVASTIGMINE TARTRATE) CAPSULE EXELON (RIVASTIGMINE TARTRATE) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]	14
MAGNESIUM STEARATE	INACTIVE INGREDIENT	70097M6I30	EXELON (RIVASTIGMINE TARTRATE) CAPSULE EXELON (RIVASTIGMINE TARTRATE) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]	14
SILICON DIOXIDE	INACTIVE INGREDIENT	ETJ7Z6XBU4	EXELON (RIVASTIGMINE TARTRATE) CAPSULE EXELON (RIVASTIGMINE TARTRATE) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]	14
SODIUM BENZOATE	INACTIVE INGREDIENT	OJ245FE5EU	EXELON (RIVASTIGMINE TARTRATE) CAPSULE EXELON (RIVASTIGMINE TARTRATE) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]	14
SODIUM CITRATE	INACTIVE INGREDIENT	1Q73Q2JULR	EXELON (RIVASTIGMINE TARTRATE) CAPSULE EXELON (RIVASTIGMINE TARTRATE) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]	14
TITANIUM DIOXIDE	INACTIVE INGREDIENT	15FIX9V2JP	EXELON (RIVASTIGMINE TARTRATE) CAPSULE EXELON (RIVASTIGMINE TARTRATE) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]	14
WATER	INACTIVE INGREDIENT	059QF0KO0R	EXELON (RIVASTIGMINE TARTRATE) CAPSULE EXELON (RIVASTIGMINE TARTRATE) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]	14
RIVASTIGMINE TARTRATE	ACTIVE INGREDIENT	9IY2357JPE	EXELON (RIVASTIGMINE TARTRATE) CAPSULE [PHYSICIANS TOTAL CARE, INC.]	1
RIVASTIGMINE	ACTIVE MOIETY	PKI06M3IW0	EXELON (RIVASTIGMINE TARTRATE) CAPSULE [PHYSICIANS TOTAL CARE, INC.]	1
CELLULOSE, MICROCRYSTALLINE	INACTIVE INGREDIENT	OP1R32D61U	EXELON (RIVASTIGMINE TARTRATE) CAPSULE [PHYSICIANS TOTAL CARE, INC.]	1
FERRIC OXIDE RED	INACTIVE INGREDIENT	1K09F3G675	EXELON (RIVASTIGMINE TARTRATE) CAPSULE [PHYSICIANS TOTAL CARE, INC.]	1
FERRIC OXIDE YELLOW	INACTIVE INGREDIENT	EX438O2MRT	EXELON (RIVASTIGMINE TARTRATE) CAPSULE [PHYSICIANS TOTAL CARE, INC.]	1
GELATIN	INACTIVE INGREDIENT	2G86QN327L	EXELON (RIVASTIGMINE TARTRATE) CAPSULE [PHYSICIANS TOTAL CARE, INC.]	1
HYPROMELLOSE	INACTIVE INGREDIENT	3NXW29V3WO	EXELON (RIVASTIGMINE TARTRATE) CAPSULE [PHYSICIANS TOTAL CARE, INC.]	1
MAGNESIUM STEARATE	INACTIVE INGREDIENT	70097M6I30	EXELON (RIVASTIGMINE TARTRATE) CAPSULE [PHYSICIANS TOTAL CARE, INC.]	1
SILICON DIOXIDE	INACTIVE INGREDIENT	ETJ7Z6XBU4	EXELON (RIVASTIGMINE TARTRATE) CAPSULE [PHYSICIANS TOTAL CARE, INC.]	1
TITANIUM DIOXIDE	INACTIVE INGREDIENT	15FIX9V2JP	EXELON (RIVASTIGMINE TARTRATE) CAPSULE [PHYSICIANS TOTAL CARE, INC.]	1

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
9IY2357JPE	RIVASTIGMINE TARTRATE	129101-54-8	RIVASTIGMINE TARTRATE

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
226665	Exelon 1.5 MG Oral Capsule	PSN	fead084a-a376-4d57-bdf0-aa7ed3655505	1
226666	Exelon 3 MG Oral Capsule	PSN	fead084a-a376-4d57-bdf0-aa7ed3655505	1
226667	Exelon 4.5 MG Oral Capsule	PSN	fead084a-a376-4d57-bdf0-aa7ed3655505	1
226668	Exelon 6 MG Oral Capsule	PSN	fead084a-a376-4d57-bdf0-aa7ed3655505	1
314214	rivastigmine tartrate 1.5 MG Oral Capsule	PSN	fead084a-a376-4d57-bdf0-aa7ed3655505	1
312835	rivastigmine tartrate 3 MG Oral Capsule	PSN	fead084a-a376-4d57-bdf0-aa7ed3655505	1
314215	rivastigmine tartrate 4.5 MG Oral Capsule	PSN	fead084a-a376-4d57-bdf0-aa7ed3655505	1
312836	rivastigmine tartrate 6 MG Oral Capsule	PSN	fead084a-a376-4d57-bdf0-aa7ed3655505	1
226665	rivastigmine 1.5 MG Oral Capsule [Exelon]	SBD	fead084a-a376-4d57-bdf0-aa7ed3655505	1
226666	rivastigmine 3 MG Oral Capsule [Exelon]	SBD	fead084a-a376-4d57-bdf0-aa7ed3655505	1
226667	rivastigmine 4.5 MG Oral Capsule [Exelon]	SBD	fead084a-a376-4d57-bdf0-aa7ed3655505	1
226668	rivastigmine 6 MG Oral Capsule [Exelon]	SBD	fead084a-a376-4d57-bdf0-aa7ed3655505	1
314214	rivastigmine 1.5 MG Oral Capsule	SCD	fead084a-a376-4d57-bdf0-aa7ed3655505	1
312835	rivastigmine 3 MG Oral Capsule	SCD	fead084a-a376-4d57-bdf0-aa7ed3655505	1
314215	rivastigmine 4.5 MG Oral Capsule	SCD	fead084a-a376-4d57-bdf0-aa7ed3655505	1
312836	rivastigmine 6 MG Oral Capsule	SCD	fead084a-a376-4d57-bdf0-aa7ed3655505	1
226665	Exelon (as rivastigmine tartrate) 1.5 MG Oral Capsule	SY	fead084a-a376-4d57-bdf0-aa7ed3655505	1
226666	Exelon (as rivastigmine tartrate) 3 MG Oral Capsule	SY	fead084a-a376-4d57-bdf0-aa7ed3655505	1
226667	Exelon (as rivastigmine tartrate) 4.5 MG Oral Capsule	SY	fead084a-a376-4d57-bdf0-aa7ed3655505	1
226668	Exelon (as rivastigmine tartrate) 6 MG Oral Capsule	SY	fead084a-a376-4d57-bdf0-aa7ed3655505	1
226665	Exelon 1.5 MG Oral Capsule	SY	fead084a-a376-4d57-bdf0-aa7ed3655505	1
226666	Exelon 3 MG Oral Capsule	SY	fead084a-a376-4d57-bdf0-aa7ed3655505	1
226667	Exelon 4.5 MG Oral Capsule	SY	fead084a-a376-4d57-bdf0-aa7ed3655505	1
226668	Exelon 6 MG Oral Capsule	SY	fead084a-a376-4d57-bdf0-aa7ed3655505	1
314214	rivastigmine 1.5 MG (as rivastigmine tartrate) Oral Capsule	SY	fead084a-a376-4d57-bdf0-aa7ed3655505	1
312835	rivastigmine 3 MG (as rivastigmine tartrate) Oral Capsule	SY	fead084a-a376-4d57-bdf0-aa7ed3655505	1
314215	rivastigmine 4.5 MG (as rivastigmine tartrate) Oral Capsule	SY	fead084a-a376-4d57-bdf0-aa7ed3655505	1
312836	rivastigmine 6 MG (as rivastigmine tartrate) Oral Capsule	SY	fead084a-a376-4d57-bdf0-aa7ed3655505	1

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
Exelon	Novartis Pharmaceuticals Corporation	2018-12-28	HUMAN PRESCRIPTION DRUG LABEL	19
Exelon - Physicians Total Care, Inc.	Physicians Total Care, Inc.	2010-06-09	HUMAN PRESCRIPTION DRUG LABEL	1